Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Sep 28;14(10):szaf037. doi: 10.1093/stcltm/szaf037

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2025. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com .

PMC Copyright notice

Figure 4. — SysBio workflow applied to data from stem cell research and therapy development.

(A) Typical SysBio workflow for scRNAseq analysis of stem cell samples. Bioinformatic workflow in SysBio assisted scRNAseq analysis of stem cell samples: scRNAseq can reveal the gene expression profile in different types of stem cells and through SysBio it is possible to identify different sets of genes being differentially expressed in each type of stem cell. Furthermore, other SysBio methods such as functional enrichment can be applied to better understand biological processes. (B) SysBio approaches can be applied in clinical stem cell therapy studies. The application of integrative SysBio methods to data generated in clinical stem cell studies can generate a better understanding for different complex diseases and enable more substantiated guidance in clinical trials.